The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Systematic review of rash in cancer patients receiving ibrutinib and idelalisib.
 
Zhe Hou
Stock and Other Ownership Interests - Regeneron (I)
 
Viswanath Reddy Belum
No Relationships to Disclose
 
Maria Lia Palomba
Consulting or Advisory Role - Pharmacyclics
 
Ysebaert Loic
No Relationships to Disclose
 
Vincent Sibaud
No Relationships to Disclose
 
Mario E. Lacouture
Honoraria - Advancell; Aveo; Bayer; BIOPHARM; Boehringer Ingelheim; Brickell Biotech; Bristol-Myers Squibb; Clinical Assistance Programs LLC; Clinical Care Options; EMD Serono; Envision Communications; Foamix; Galderma; Genentech/Roche; GlaxoSmithKline; Helsinn Healthcare; Helsinn Healthcare; Medscape; Merck; NeRRe Therapeutics; Novartis; Novocure; Oncology Specialty Group; Pfizer; Pierre Fabre; Threshold Pharmaceuticals
Consulting or Advisory Role - Bayer; Boehringer Ingelheim; Brickell Biotech; Bristol-Myers Squibb; EMD Serono; Foamix; Galderma; Genentech/Roche; GlaxoSmithKline; Helsinn Healthcare; Merck; Novartis; Novocure; Pfizer; Pierre Fabre; Threshold Pharmaceuticals
Research Funding - Berg Pharma (Inst)